Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Dec;9(10):1058-69.
doi: 10.2174/187152009789735017.

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

Tristan M Sissung  1 , Silja Thordardottir, Erin R Gardner, William D Figg
Affiliations
Review

Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer

Tristan M Sissung et al. Anticancer Agents Med Chem. 2009 Dec.

Abstract

Thalidomide is emerging as a potentially important therapeutic option in the treatment of metastatic prostate cancer. Although the mechanism of action of this agent remains elusive in malignancies of the prostate, recent data has indicated that thalidomide may play a role in inflammation, immunomodulation, and anti-angiogenesis. Lenalidomide (CC-5013), a thalidomide analogue with improved activity and safety profile in certain disease contexts, is in the early stages of development in prostate cancer. This review will provide the current status of the history, mechanism, metabolism, and clinical use of thalidomide in metastatic prostate cancer. It will also describe the mechanism and clinical use of lenalidomide as it pertains to malignancies of the prostate.

PubMed Disclaimer

Figures

Fig. (1).
Fig. (1).
Thalidomide, CC-5013, CC4047.
Fig. (2).
Fig. (2).
Thalidomide hydrolysis products. Adapted from [55]. The names of all compounds are listed in Table 1 alongside their respective numbers.
Fig.(3).
Fig.(3).
Thalidomide metabolites. Adapted from[55]. The names of all compounds are listed in Table 1alongside their respective numbers.
See this image and copyright information in PMC

References

    1. Jemal A; Siegel R; Ward E; Hao Y; Xu J; Murray T; Thun MJ Cancer statistics:2008. CA Cancer J. Clin., 2008, 58(2), 71–96. - PubMed
    1. Petrylak DP; Tangen CM; Hussain MH; Lara PN Jr.; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med, 2004,351(15), 1513–20. - PubMed
    1. Tannock IF; de Wit R; Berry WR; Horti J; Pluzanska A; Chi KN; Oudard S; Theodore C; James ND; Turesson I; Rosenthal MA; Eisenberger MA Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351(15), 1502–12. - PubMed
    1. Lenz W; Pfeiffer R; Kosenow W; Hayman D Thalidomide and [26] congenital abnormalities. Lancet, 1962, 27945–46.
    1. McBride W Thalidomide and congenital abnormalities. Lancet, 1961,

Publication types